- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07806409
Safety and Clinical Performance of the Next-Generation SAFESYNC Transcatheter Heart Valve in Patients With Severe Aortic Stenosis (SAFESYNC NG)
3 de setembro de 2026 atualizado por: Braile Biomedica Ind. Com. e Repr. Ltda.
Evaluation of the Safety and Clinical Performance of the Next-Generation SAFESYNC Balloon-Expandable Transcatheter Heart Valve in Patients With Severe Aortic Stenosis: A Prospective, Multicenter, Single-Arm Pivotal Study
The objective of this pivotal, prospective, multicenter, single-arm clinical trial is to evaluate the safety and clinical performance of the Next-Generation INOVARE® SAFESYNC Bioprosthetic Heart Valve, implanted via a transcatheter approach, in patients with severe aortic stenosis, an indication for TAVI, and intermediate or higher surgical risk.
The study will enroll 40 participants.
Visão geral do estudo
Status
Ainda não está recrutando
Intervenção / Tratamento
Tipo de estudo
Intervencional
Inscrição (Estimado)
40
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Contato de estudo
- Nome: Clinical Research Department - Braile Biomédica
- Número de telefone: +5517 21367000
- E-mail: pesquisa@braile.com.br
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Não
Descrição
Inclusion Criteria:
- Severe aortic valve stenosis diagnosed according to criteria established in current guidelines.
- Intermediate or higher surgical risk, defined as a Society of Thoracic Surgeons (STS) score ≥4%.
- Indication for transcatheter aortic valve implantation (TAVI).
- Willing and able to participate in the study and provide written informed consent.
Exclusion Criteria:
- Any condition considered a contraindication to implantation of a bioprosthetic heart valve (e.g., indication for a mechanical heart valve).
- Known hypersensitivity or contraindication to aspirin, clopidogrel, heparin, nitinol (titanium or nickel), or contrast media that cannot be adequately managed with premedication. This includes heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia with thrombosis (HITTS).
- Blood dyscrasias, including leukopenia (white blood cell count <1,000/mm³), thrombocytopenia (platelet count <100,000 cells/mm³), history of coagulopathy, or hypercoagulable states.
- Active infection, including endocarditis.
- Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or requirement for mechanical hemodynamic support.
- Stroke or transient ischemic attack (TIA) within 2 months prior to the index procedure.
- History of gastrointestinal bleeding or other bleeding that precludes anticoagulant or antiplatelet therapy.
- Estimated life expectancy of less than 24 months.
- Other medical, social, or psychological conditions that, in the investigator's opinion, may prevent the participant from providing informed consent or adequately complying with the study protocol.
- Pre-existing prosthetic heart valve, either biological or mechanical, in the aortic position.
- Concomitant severe mitral or tricuspid valve disease.
- Hypertrophic obstructive cardiomyopathy.
- Successful percutaneous coronary intervention (PCI) performed within 48 hours prior to TAVI.
- Femoral artery diameter <5.5 mm for SAFESYNC 20-24 mm, <6.0 mm for SAFESYNC 26-28 mm, or <6.5 mm for SAFESYNC 30 mm.
- High risk of aortic annular rupture or significant residual paravalvular leak due to severe calcification of the aortic valve or left ventricular outflow tract.
- High risk of coronary obstruction, defined by computed tomography angiography as coronary ostial height <10 mm with narrow sinuses of Valsalva (SOV), with a mean SOV diameter <3 mm greater than the bioprosthetic valve size.
- Left ventricular dysfunction with left ventricular ejection fraction (LVEF) ≤30%.
- Severe chronic kidney disease, defined as glomerular filtration rate (GFR) <30 mL/min/1.73 m².
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: INOVARE® SAFESYNC Next-Generation TAVI
|
Participants will undergo TAVI via transfemoral access using the INOVARE® SAFESYNC Next-Generation Bioprosthetic Heart Valve and the B-Delivery System.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Device Success According to VARC-3 Criteria
Prazo: 30 days after the procedure
|
Technical success; Absence of mortality; Absence of surgery or intervention related to the device or to major vascular, access-related, or cardiac structural complications; Intended valve performance, defined as mean transvalvular gradient <20 mmHg, peak velocity <3 m/s, Doppler velocity index ≥0.25, and less than moderate aortic regurgitation.
|
30 days after the procedure
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Percentage of Participants Achieving Technical Success According to VARC-3 Criteria
Prazo: During the procedure
|
Defined as freedom from mortality; successful vascular access, delivery of the device, and retrieval of the delivery system; correct positioning of a single prosthetic heart valve in the intended anatomical location; and freedom from surgery or intervention related to the device or to a major vascular, access-related, or cardiac structural complication.
Results will be reported as the number and percentage of participants achieving technical success.
|
During the procedure
|
|
Incidence and Severity of Paravalvular Leak
Prazo: 30 days, 6 months, 12 months, and annually through 5 years
|
Paravalvular leak will be assessed by transthoracic echocardiography and classified according to severity.
The number and percentage of participants with paravalvular leak in each severity category will be reported.
|
30 days, 6 months, 12 months, and annually through 5 years
|
|
Mean Transvalvular Aortic Pressure Gradient Assessed
Prazo: 30 days, 6 months, 12 months, and annually through 5 years
|
Mean transvalvular aortic pressure gradient will be assessed by transthoracic echocardiography and reported in mmHg.
|
30 days, 6 months, 12 months, and annually through 5 years
|
|
Distribution of Participants by New York Heart Association Functional Class
Prazo: 30 days, 6 months, 12 months, and annually through 5 years
|
Functional status will be assessed using the New York Heart Association (NYHA) Functional Classification.
The classification ranges from Class I to Class IV, where Class I represents no limitation of physical activity and Class IV represents inability to perform physical activity without symptoms and/or symptoms at rest.
Higher NYHA classes indicate worse functional status.
Results will be reported as the number and percentage of participants in each NYHA functional class.
|
30 days, 6 months, 12 months, and annually through 5 years
|
|
Incidence of New Permanent Pacemaker Implantation
Prazo: 30 days, 6 months, 12 months, and annually through 5 years
|
New permanent pacemaker implantation following the index transcatheter aortic valve implantation procedure will be assessed.
Results will be reported as the number and percentage of participants who undergo new permanent pacemaker implantation.
|
30 days, 6 months, 12 months, and annually through 5 years
|
|
Incidence of All-Cause Mortality
Prazo: 30 days, 6 months, 12 months, and annually through 5 years
|
All-cause mortality will be assessed throughout follow-up.
Results will be reported as the number and percentage of participants who die from any cause.
|
30 days, 6 months, 12 months, and annually through 5 years
|
|
Incidence of Stroke
Prazo: 30 days, 6 months, 12 months, and annually through 5 years
|
Stroke events will be assessed based on clinical neurological evaluation and classified according to Valve Academic Research Consortium 3 (VARC-3) definitions.
Results will be reported as the number and percentage of participants experiencing stroke.
|
30 days, 6 months, 12 months, and annually through 5 years
|
|
Incidence of Bioprosthetic Valve-Related Reintervention
Prazo: 30 days, 6 months, 12 months, and annually through 5 years
|
Bioprosthetic valve-related reintervention will be defined as any surgical or transcatheter intervention performed to treat dysfunction or failure of the implanted study valve.
Results will be reported as the number and percentage of participants undergoing valve-related reintervention.
|
30 days, 6 months, 12 months, and annually through 5 years
|
|
Incidence of Bioprosthetic Valve Dysfunction According to VARC-3 Definitions
Prazo: 30 days, 6 months, 12 months, and annually through 5 years
|
Bioprosthetic valve dysfunction will be assessed according to Valve Academic Research Consortium 3 (VARC-3) definitions.
Bioprosthetic valve dysfunction includes structural valve deterioration, non-structural valve dysfunction, valve thrombosis, and endocarditis.
Results will be reported as the number and percentage of participants meeting the criteria for bioprosthetic valve dysfunction and according to the corresponding category.
|
30 days, 6 months, 12 months, and annually through 5 years
|
|
Incidence of Bioprosthetic Valve Failure According to VARC-3 Definitions
Prazo: 30 days, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months after the index procedure
|
Bioprosthetic valve failure will be assessed according to Valve Academic Research Consortium 3 (VARC-3) definitions.
Results will be reported as the number and percentage of participants meeting the criteria for bioprosthetic valve failure.
|
30 days, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months after the index procedure
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Estimado)
1 de novembro de 2026
Conclusão Primária (Estimado)
1 de julho de 2027
Conclusão do estudo (Estimado)
1 de junho de 2032
Datas de inscrição no estudo
Enviado pela primeira vez
19 de agosto de 2026
Enviado pela primeira vez que atendeu aos critérios de CQ
3 de setembro de 2026
Primeira postagem (Real)
8 de setembro de 2026
Atualizações de registro de estudo
Última Atualização Postada (Real)
8 de setembro de 2026
Última atualização enviada que atendeu aos critérios de controle de qualidade
3 de setembro de 2026
Última verificação
1 de setembro de 2026
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- SAFESYNC NG
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
NÃO
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .